Overview

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, placebo-controlled, double-blind, multi-center study to evaluate efficacy and safety of different doses of CS-3150 compared to placebo in Japanese hypertensive subjects. Primary endpoint is change from baseline in sitting systolic and diastolic blood pressure.
Phase:
Phase 2
Details
Lead Sponsor:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.
Treatments:
Eplerenone
Mineralocorticoid Receptor Antagonists